The phase III randomized, controlled trial was conducted in Latin America, Asia, Africa and Europe during the 2014-15 and 2015-16 flu seasons in the Northern Hemisphere and the 2014 and 2015 flu seasons in the Southern Hemisphere. Children aged 6 months to 35 months, who had not previously been vaccinated, were divided into four groups receiving two full doses of IIV4, placebo, the licensed trivalent split-virion inactivated vaccine or an investigational trivalent vaccine.
The study included 5,806 participants, and efficacy of IIV4 was demonstrated for 4,980 participants. IIV4 vaccine efficacy was 50.98 percent against influenza caused by any A or B type and 68.4 percent against influenza caused by vaccine-like strains.
More articles on healthcare quality:
How a 3D model helps Penn State Children’s give better heart care
C. diff spores persist in toilet, bathroom environment even after flushing
Can vitamin-steroid cocktail cure sepsis? Trial aims to find out
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
